Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461821 | 1.00 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1HSP90B1TRAP1PRKCQ | |
| SCHEMBL461325 | 0.90 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1PRKCQAMY1A | |
| SCHEMBL461324 | 0.90 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1PRKCQAMY1A | |
| SCHEMBL462027 | 0.87 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL462028 | 0.87 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL2181661 | 0.84 | HSP90AA1 (0.36) | HSP90AA1PRKCQPRKCDAMY1A | |
| SCHEMBL1076054 | 0.83 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1PRKCQAMY1A | |
| SCHEMBL1078057 | 0.82 | HSP90AA1 (0.47) | HSP90AA1PRKCQPRKCDAMY1A | |
| SCHEMBL425958 | 0.81 | HSP90AA1 (0.64) | HSP90AA1 | |
| SCHEMBL425959 | 0.81 | HSP90AA1 (0.64) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408762-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
| WO-2010106290-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885HSP90B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.